Featured Suppliers:

Ads by Google


 

Inovio Biomedical Corporation


News and Blogs

Total : 1 View more »

Inovio Biomedical Board of Directors Adds Two New Members

www.pharmiweb.com

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Avent

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9125

 

xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 20, 2009 : INO, HOL, FSP and CXZ

Xtremepicks.com Alerts include Inovio Biomedical Corporation (NYSE Amex: INO), China Holdings Acquisition Corp. (AMEX: HOL), Franklin Street Properties Corp. (NYSE Amex: FSP) and Crosshair Exploration & Mining Corp. (TSX:CXX)(NYSE Amex: CXZ)

Inovio Biomedical Corporation (NYSE Amex:INO) trading at $1.54 per share on trading volume of 8.09M shares.

In a press release out on November 20, Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies

Inovio's SynCon(TM) Universal Flu Vaccines Provide 100% Protection in Ferrets against Death and Sickness in a Challenge Study with the Pandemic H1N1 Virus

SAN DIEGO, Nov 20, 2009 -- Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets. In addition, ferrets immunized with Inovio's SynCon(TM) universal flu vaccine combinations were 100% protected against death and sickness in a challenge with the A/H1N1 (2009) swine-origin influenza. Dr. Niranjan Y. Sardesai, Inovio's SVP, Research and Development, presented this data at the Influenza Congress USA 2009 in Washington, DC, in a presentation titled, "Development of Universal SynCon(TM) DNA Vaccines for Pandemic and Seasonal Influenza."

About Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company's SynCon(TM) technology enables the design of "universal" vaccines capable of protecting against multiple -- including newly emergent, unknown -- strains of pathogens such as influenza. Inovio's proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio's clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH's Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available atwww.inovio.com.

China Holdings Acquisition Corp. (AMEX:HOL) trading at $9.75 per share on trading volume of 24,080 shares.

In a press release out on November 20, China Holdings Acquisition Corp. Announces Approval of the Business Combination with Jinjiang Hengda Ceramics

WILMINGTON, Del., Nov 20, 2009 -- China Holdings Acquisition Corp. (AMEX:HOL) (the "Company" or "CHAC"), a special purpose acquisition company, today announced its stockholders approved the Company's previously announced proposed business combination with Success Winner Limited, CHAC's target company and the parent entity of Jinjiang Hengda Ceramics Co., Ltd. ("Hengda"). Hengda is a leading Chinese manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings. The companies expect to consummate the business combination later today.

About China Holdings Acquisition Corp.

Founded in 2007, China Holdings Acquisition Corp. ("CHAC") is a blank check company focused on acquiring companies with primary operations in Asia through a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination or contractual arrangements. CHAC currently has no operating businesses

Franklin Street Properties Corp. (NYSE Amex: FSP) trading at $10.86 on a volume of 157,595 shares

In a press release out on November 20, Franklin Street Properties Corp. Achieves the First Existing Buildings: Operations & Maintenance Leed(R) Certification in the State of Indiana

WAKEFIELD, MA, Nov 20, 2009 -- Franklin Street Properties Corp. ("FSP", "we", "our" or "its") (NYSE Amex: FSP), an investment firm specializing in real estate, today announced that its office buildings located at 3815 and 3925 River Crossing Parkway, Indianapolis, Indiana, have received LEED Silver Certification by the U.S. Green Building Council ("USGBC") in the Leadership in Energy and Environmental Design ("LEED") for Existing Buildings: Operations & Maintenance ("LEED-EB: O&M").

About Franklin Street Properties Corp.

Franklin Street Properties Corp., based in Wakefield, Massachusetts, is focused on achieving current income and long-term growth through investments in commercial properties. FSP operates in two business segments: real estate operations and investment banking/investment services. The majority of FSP's property portfolio is suburban office buildings, with select investments in certain central business district properties. FSP's subsidiary, FSP Investments LLC (member, FINRA and SIPC), is a real estate investment banking firm and a registered broker/dealer. FSP is a Maryland corporation that operates in a manner intended to qualify as a real estate investment trust (REIT) for federal income tax purposes. To learn more about FSP please visit our website atwww.franklinstreetproperties.com.

Crosshair Exploration & Mining Corp. (TSX:CXX)(NYSE Amex:CXZ) trading at $0.208 on a volume of 31,900 shares

In a press release out on November 20, Crosshair Closes Concurrent Private Placements for Gross Proceeds of $2,275,000

VANCOUVER, BRITISH COLUMBIA, Nov 20, 2009 -- Crosshair Exploration & Mining Corp. (TSX:CXX)(NYSE Amex:CXZ) ("Crosshair") is pleased to announce the closing on November 19, 2009 of a brokered private placement with Byron Securities Limited (the "Agent") of 5,000,000 units (the "Units") to Canadian accredited investors at a price of $0.20 per Unit for gross proceeds of $1,000,000 (the "Unit Private Placement"). Each Unit consists of one common share in the capital of Crosshair (a "Common Share") and one common share purchase warrant (a "Warrant") with each Warrant exercisable for one Common Share at an exercise price of $0.30 per Common Share for 24 months from November 19, 2009.

About Crosshair

Crosshair is a dominant player in the exploration and development of uranium and gold in the US and Canada. Its flagship Project, Bootheel, is located in uranium mining friendly Wyoming and with its in-situ mining potential, Bootheel is designed for near term production. The CMB Uranium Project is located in Labrador, Canada and has four currently defined resources - C Zone, Area 1, Armstrong and Two Time Zone. The Crosshair team is comprised of knowledgeable and experienced professionals with both exploration and mining backgrounds.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Read more...

Tags: acquisition   amex   asia   biomedical   british columbia   broker   business   canada   cancer   china   clinical   commercial   congress   dealer   dna   email   e-mail   energy   exercise   exploration   federal   gold   health   hiv   indiana   investment   investment banking   investment opinion   manufacturer   maryland   massachusetts   merger   mining   national cancer institute   nyse   pennsylvania   Private Placement   products   profit   property   real estate   reit   research   research and development   residential   securities   silver   swine   tax   technology   trial   university   vaccine   vancouver   washington dc   web   wyoming  

Companies: China Holdings Acquisition Corp (HOL), China Holdings Acquisition Corp (HOL/U), Crosshair Exploration & Mining Corp (CXX), Crosshair Exploration & Mining Corp (CXZ), Franklin Street Properties Corp (FSP), Inovio Biomedical Corp (INO)

 

Inovio Biomedical Corp. (INO) Corporate Event Announcement Notice - Zibb.com

Inovio Biomedical Corp. (INO)
Expected next earnings release:
Announcement date: 3/31/2010 - Before Market
Earnings Quarter: Q4
Announcement Status: Unconfirmed

Tags: biomedical   corporate   earnings   market  

Companies: Inovio Biomedical Corp (INO)

 

Inovio Biomedical Corp. (INO) Corporate Event Announcement Notice - Zibb.com

Inovio Biomedical Corp. (INO)
Expected next earnings release:
Announcement date: 11/16/2009 - Before Market
Earnings Quarter: Q3
Announcement Status: Verified

Tags: biomedical   corporate   earnings   market  

Companies: Inovio Biomedical Corp (INO)

 

Inovio Biomedical Corp. (INO) Corporate Event Announcement Notice - Zibb.com

Inovio Biomedical Corp. (INO)
Expected next earnings release:
Announcement date: 11/18/2009 - After Market
Earnings Quarter: Q3
Announcement Status: Unconfirmed

Tags: biomedical   corporate   earnings   market  

Companies: Inovio Biomedical Corp (INO)

 

Web Sites

Total : 30 View more »

Inovio » Privacy

Inovio Biomedical Corporation collects information from our website users, subscribers and other customers. In this section of our Privacy Statement, we describe the type of information we collect and how we use it to provide better services to our customers.

http://www.inovio.com/privacy.htm

Medical Daily : Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces ...

Therapeutic DNA Vaccine Company Inovio Biomedical Corp. Announces ...SAN DIEGO -- Inovio Biomedical Corp. (AMEX:INO), a leader in enabling the development of therapeutic DNA vaccines for cancers and infectious diseases using ...

http://www.medicaldaily.net/frame_linktop.asp?ID=258168

Biospace.com

Amgen (AMGN) (Jobs) Shares Drop, Hit by More Anemia-Drug Fallout NEW YORK, May 15 (Reuters) - Another setback for Amgen Inc.'s anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.

http://www.biospace.com/news_category.aspx?CategoryID=36

Pharmacy Choice - Pharmaceutical News - Inovio Biomedical Partner Tripep Files Application for

The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C(R), administered using Inovio's MedPulser(R) DNA Delivery System. This combination is designed to activate a T-cell response capable of clearing hepatitis C virus.

http://www.pharmacychoice.com/News/article.cfm?Article_ID=43141

Web Sites powered by Bing

Total : 19,400 View more »

Inovio Biomedical Corporation

inovio.com

Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy.

http://inovio.com/

Inovio Biomedical Corporation (INO) Company Profile ...

www.corporateinformation.com

Inovio Biomedical Corporation. The Group's principal activity is to develop and commercializing novel medical therapies to cure diseases with critical unmet treatment needs using ...

http://www.corporateinformation.com/Company-Snapshot.aspx?cusip=45773H102

Inovio » About Us »

www.inovio.com

Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation therapy.

http://www.inovio.com/aboutus/career.htm